Delivery Order SPE2DB24D3013-SPE2DB25FFRBW
Award Date 9/29/25
Potential Completion Date 10/21/25
Potential Value $8.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Ibrance 75 mg tablets (quantity 7) with a ceiling value of $8,123.96 and firm fixed pricing. This is a non-set-aside competitive award with an ultimate completion date of October 16, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibrance 75 mg tablets in a quantity of seven units, with a ceiling value of $32,495.84. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for ultimate completion on October 8, 2025, with performance taking place at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ibrance 100 mg tablets in 7-count packaging, with a contract ceiling value of $24,367.44 and completion date of October 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with the federal government. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-count), valued at $8,122.48 under a firm fixed price contract. This non-set-aside delivery order is scheduled for completion by September 3, 2025, with performance of work occurring at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets (7-count packages) with a ceiling value of $8,122.48. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was competitively awarded with no set-aside designation. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, supporting the federal government's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 75 mg tablets in quantities of seven units, with a contract ceiling value of $8,123.96. This competitively awarded, firm fixed-price delivery order is set to be completed by September 24, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets in quantities of seven units. This firm fixed price delivery order, valued at $32,489.92, represents a competitive award with no set-aside designation and is scheduled for completion by September 24, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 27, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, valued at $8,118.08. This is a firm fixed-price delivery order with an ultimate completion date of June 17, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate operations as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 100 mg tablets (quantity 7s) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with a completion date of September 30, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...